MX2021013018A - Formulacion de arnm. - Google Patents
Formulacion de arnm.Info
- Publication number
- MX2021013018A MX2021013018A MX2021013018A MX2021013018A MX2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A
- Authority
- MX
- Mexico
- Prior art keywords
- mrna
- present
- mrna molecules
- combinations
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19171323 | 2019-04-26 | ||
| PCT/EP2020/061477 WO2020216911A1 (en) | 2019-04-26 | 2020-04-24 | Mrna formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013018A true MX2021013018A (es) | 2022-03-11 |
Family
ID=66290283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013018A MX2021013018A (es) | 2019-04-26 | 2020-04-24 | Formulacion de arnm. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220362360A1 (enExample) |
| EP (1) | EP3958893A1 (enExample) |
| JP (1) | JP7650001B2 (enExample) |
| KR (1) | KR20220023340A (enExample) |
| CN (1) | CN114096272B (enExample) |
| AU (1) | AU2020263948B2 (enExample) |
| BR (1) | BR112021021262A2 (enExample) |
| CA (1) | CA3138011A1 (enExample) |
| IL (1) | IL287560B2 (enExample) |
| MX (1) | MX2021013018A (enExample) |
| SG (1) | SG11202111720TA (enExample) |
| WO (1) | WO2020216911A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7496623B2 (ja) * | 2019-01-04 | 2024-06-07 | イーザアールエヌーエー イムノセラピーズ エンヴェー | ｍＲＮＡワクチン |
| US20220143161A1 (en) * | 2019-03-13 | 2022-05-12 | Etherna Immunotherapies Nv | Mrna vaccine |
| CN119701015A (zh) * | 2023-09-26 | 2025-03-28 | 深圳瑞吉生物科技有限公司 | 一种细胞因子mRNA组合药物及其应用 |
| CN121873266A (zh) * | 2026-03-18 | 2026-04-17 | 北京悦康科创医药科技股份有限公司 | 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2201100E (pt) * | 2007-09-14 | 2016-06-03 | Univ Brussel Vrije | Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação |
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| EP3173474A1 (en) * | 2007-09-14 | 2017-05-31 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| WO2015071295A1 (en) | 2013-11-12 | 2015-05-21 | Vrije Universiteit Brussel | Rna transcription vector and uses thereof |
| DK4276189T3 (da) * | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| MA47515A (fr) * | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
-
2020
- 2020-04-24 US US17/604,559 patent/US20220362360A1/en active Pending
- 2020-04-24 CN CN202080038101.1A patent/CN114096272B/zh active Active
- 2020-04-24 JP JP2021563262A patent/JP7650001B2/ja active Active
- 2020-04-24 CA CA3138011A patent/CA3138011A1/en active Pending
- 2020-04-24 WO PCT/EP2020/061477 patent/WO2020216911A1/en not_active Ceased
- 2020-04-24 KR KR1020217038364A patent/KR20220023340A/ko active Pending
- 2020-04-24 AU AU2020263948A patent/AU2020263948B2/en active Active
- 2020-04-24 MX MX2021013018A patent/MX2021013018A/es unknown
- 2020-04-24 EP EP20721229.1A patent/EP3958893A1/en active Pending
- 2020-04-24 BR BR112021021262A patent/BR112021021262A2/pt unknown
- 2020-04-24 SG SG11202111720TA patent/SG11202111720TA/en unknown
- 2020-04-24 IL IL287560A patent/IL287560B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021021262A2 (pt) | 2021-12-21 |
| SG11202111720TA (en) | 2021-11-29 |
| AU2020263948B2 (en) | 2026-06-25 |
| CN114096272B (zh) | 2024-08-06 |
| EP3958893A1 (en) | 2022-03-02 |
| CN114096272A (zh) | 2022-02-25 |
| WO2020216911A1 (en) | 2020-10-29 |
| JP7650001B2 (ja) | 2025-03-24 |
| IL287560B2 (en) | 2026-02-01 |
| US20220362360A1 (en) | 2022-11-17 |
| AU2020263948A1 (en) | 2021-12-23 |
| CA3138011A1 (en) | 2020-10-29 |
| IL287560B1 (en) | 2025-10-01 |
| JP2022532038A (ja) | 2022-07-13 |
| KR20220023340A (ko) | 2022-03-02 |
| IL287560A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004936A (es) | Variantes de capsides de aav y sus usos. | |
| CL2024000410A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| CR20200196A (es) | Proteínas trispecìficas y mètodos de uso | |
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| MX2024009660A (es) | Variantes de capside de aav y usos de las mismas. | |
| ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| MX2019012452A (es) | Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| EA201991951A1 (ru) | Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| EP4374851A3 (en) | Ophthalmic composition for treatment of dry eye disease | |
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| BR112021021262A2 (pt) | Formulação de mrna | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| CL2017003201A1 (es) | Variantes de il-37 | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| SA520420261B1 (ar) | تركيبات إرنوماب واستخداماتها | |
| PH12019500949A1 (en) | Ror-gamma modulators | |
| BR112021014566A2 (pt) | Moduladores de gpr35 | |
| EA202090063A1 (ru) | Композиции и способы для лечения таупатий | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| MX2021008126A (es) | Vacuna de arnm. |